Brazil completes II phase trial of COVID-19 vaccine

The first vaccine against coronavirus infection, based entirely on Brazilian technology and components, has entered the third phase of clinical trials. It will start in 2026 with more than 5,000 volunteers, according to the website of the Brazilian Ministry of Science, Technology and Innovation.

More than 300 people participated in the second phase of the trial, with no serious side effects recorded.

The distinctive feature of the vaccine is its innovative mechanism of action: it not only stimulates the production of antibodies, but also helps the body to destroy infected cells, which increases its effectiveness against new mutations of the virus. In addition, the report says that the vaccine can be stored in ordinary refrigerators, making it easier to transport and distribute.

If the third phase is successful, the vaccine will be sent to Brazil's National Health Surveillance Agency for registration, after which it will become available for mass use.

Photo: iStock